Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger L Albin

Showing results (111-120 of 242) with videos related to

Pageof 25
Sort By:
Experimental Neurology|September 6, 2003
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexoleElyse S Kemmerer, Timothy J Desmond, Roger L Albin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 13, 2009
In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington diseaseMary Y Heng, Peter J Detloff, Phillip L Wang, et al.
Neural Regeneration Research|May 27, 2026
Cholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's diseaseNicolaas I Bohnen, Stiven Roytman, Giulia Carli, et al.
Journal of Parkinson'S Disease|January 21, 2017
Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson DiseaseVikas Kotagal, Nicolaas I Bohnen, Martijn L T M Müller, et al.
Clinical Therapeutics|September 23, 2008
Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudyPatrick D Mauldin, Paulo Guimaraes, Roger L Albin, et al.
Annals of Clinical and Translational Neurology|February 13, 2026
Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson DiseaseTaylor Brown, Giulia Carli, Prabesh Kanel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imagingRoger L Albin, James F Burke, Robert A Koeppe, et al.
Parkinsonism & Related Disorders|December 18, 2024
Regional cerebral cholinergic vesicular transporter correlates of visual contrast sensitivity in Parkinson's disease: Implications for visual and cognitive functionTaylor Brown, Prabesh Kanel, Alexis Griggs, et al.
Journal of Geriatric Psychiatry and Neurology|December 20, 2002
Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphologySatoshi Minoshima, Norman L Foster, Eric C Petrie, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|February 11, 2021
Huntington's Disease Community Perspectives on Desired Characteristics of Disease Modifying TherapiesMichele C Gornick, Kerry A Ryan, Praveen Dayalu, et al.
Pageof 25

Showing results (111-120 of 242) with videos related to

Sort By:
Pageof 25
Experimental Neurology|September 6, 2003
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexoleElyse S Kemmerer, Timothy J Desmond, Roger L Albin, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 13, 2009
In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington diseaseMary Y Heng, Peter J Detloff, Phillip L Wang, et al.
Neural Regeneration Research|May 27, 2026
Cholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's diseaseNicolaas I Bohnen, Stiven Roytman, Giulia Carli, et al.
Journal of Parkinson'S Disease|January 21, 2017
Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson DiseaseVikas Kotagal, Nicolaas I Bohnen, Martijn L T M Müller, et al.
Clinical Therapeutics|September 23, 2008
Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudyPatrick D Mauldin, Paulo Guimaraes, Roger L Albin, et al.
Annals of Clinical and Translational Neurology|February 13, 2026
Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson DiseaseTaylor Brown, Giulia Carli, Prabesh Kanel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 11, 2013
Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imagingRoger L Albin, James F Burke, Robert A Koeppe, et al.
Parkinsonism & Related Disorders|December 18, 2024
Regional cerebral cholinergic vesicular transporter correlates of visual contrast sensitivity in Parkinson's disease: Implications for visual and cognitive functionTaylor Brown, Prabesh Kanel, Alexis Griggs, et al.
Journal of Geriatric Psychiatry and Neurology|December 20, 2002
Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphologySatoshi Minoshima, Norman L Foster, Eric C Petrie, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|February 11, 2021
Huntington's Disease Community Perspectives on Desired Characteristics of Disease Modifying TherapiesMichele C Gornick, Kerry A Ryan, Praveen Dayalu, et al.
Pageof 25